What this pack is
INDERAL LA is the brand name in this record; propranolol hydrochloride is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
INDERAL LAGeneric namepropranolol hydrochloride
How this medicine works
The U.S. public label describes propranolol as a nonselective beta-adrenergic receptor-blocking agent that competes with beta-receptor stimulating agents for available receptor sites. This mechanism helps read drug class and label cautions; it does not determine an individual's heart rate, blood pressure, breathing status, suitability, capsule count, capsule opening or any combination plan.
Read source: United States ↗reviewed 2026-08-23More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- INDERAL LA
- Generic name
- propranolol hydrochloride
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · U.S. DailyMed public label (updated 1 Aug 2024); cited label record only, not availability
Propranolol hydrochloride 60 mg per capsule; 100-capsule bottle
- Product code
- NDC 62559-520-01
- Form and route
- INDERAL LA propranolol hydrochloride extended-release oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- propranolol hydrochloride
- 60 mglabelled amount per extended-release capsule; not an individual's capsule count, frequency, opening, co-use or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- white/light blue · extended-release capsule; appearance only helps check the exact labelled product · imprint INDERAL LA / 60
United States label · U.S. DailyMed public label (updated 1 Aug 2024); cited label record only, not availability
Propranolol hydrochloride 80 mg per capsule; 100-capsule bottle
- Product code
- NDC 62559-521-01
- Form and route
- INDERAL LA propranolol hydrochloride extended-release oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- propranolol hydrochloride
- 80 mglabelled amount per extended-release capsule; not an individual's capsule count, frequency, opening, co-use or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- light blue · extended-release capsule; appearance only helps check the exact labelled product · imprint INDERAL LA / 80
United States label · U.S. DailyMed public label (updated 1 Aug 2024); cited label record only, not availability
Propranolol hydrochloride 120 mg per capsule; 100-capsule bottle
- Product code
- NDC 62559-522-01
- Form and route
- INDERAL LA propranolol hydrochloride extended-release oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- propranolol hydrochloride
- 120 mglabelled amount per extended-release capsule; not an individual's capsule count, frequency, opening, co-use or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- light blue/dark blue · extended-release capsule; appearance only helps check the exact labelled product · imprint INDERAL LA / 120
United States label · U.S. DailyMed public label (updated 1 Aug 2024); cited label record only, not availability
Propranolol hydrochloride 160 mg per capsule; 100-capsule bottle
- Product code
- NDC 62559-523-01
- Form and route
- INDERAL LA propranolol hydrochloride extended-release oral capsule · oral (label product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-23; actual marketing, stock and availability are not established.
- propranolol hydrochloride
- 160 mglabelled amount per extended-release capsule; not an individual's capsule count, frequency, opening, co-use or conversion instruction
- Package
- 100 capsules per bottle
- Labelled appearance
- dark blue · extended-release capsule; appearance only helps check the exact labelled product · imprint INDERAL LA / 160
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
INDERAL LA label reading: extended-release capsules and mg identify a product; they do not answer “how to switch or how many capsules”
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module reads only INDERAL LA, propranolol hydrochloride, extended-release oral capsules, labelled amount per capsule, NDCs, packaging and key warnings in the U.S. DailyMed public label. It provides no individual capsule count, timing, capsule opening, co-use, stopping, switching or purchase plan.
- Check INDERAL LA, propranolol hydrochloride, extended-release oral-capsule form, the stated 60/80/120/160 mg per capsule, actual NDC, 100-capsule bottle and target market together. The label expressly says this extended-release product is not a simple mg-for-mg substitute for conventional propranolol; mg is an exact-capsule identity field, not a web conversion or switching rule.
- The extended-release capsule name, appearance and package only help identify the exact product. Whether a capsule may be opened, how to address swallowing difficulty, or whether another form or strength is needed must be confirmed from the actual prescription, current label and a pharmacist or prescriber—not from a prior pack, a similar mg number or this webpage.
- The label contains cautions involving abrupt discontinuation, cardiac risks, bronchospastic lung disease, heart failure, masking of hyperthyroid signs and other medicines on the list. These need professional review in the actual context. Do not self-start, adjust, stop, combine, alternate or replace it because of a feeling, a conventional tablet with the same generic name or another same-class pack.
- With fainting, breathing difficulty, marked palpitations/abnormal heart rate, chest pain, a severe allergic reaction or another acute serious concern, prioritise local emergency medical care. Do not wait for a web search or self-counteract or test with another pack.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-23
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): U.S. INDERAL LA propranolol hydrochloride extended-release oral-capsule public label (ANI; updated 1 Aug 2024) ↗reviewed 2026-08-23
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about INDERAL LA (propranolol hydrochloride). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
INDERAL LA is the brand in this record and propranolol hydrochloride is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How propranolol works: the nonselective beta-receptor blocking pathway described in the label
- “Nonselective beta blocker” is a mechanism and class clue; it does not permit self-combining, alternating, substituting or milligram-converting with a conventional propranolol tablet, another extended-release product or another beta blocker. The exact product, strength, release design, target-market label, prior reactions and complete medicine list all need review together.
- A mechanism or a labelled indication cannot let a webpage decide whether a person is suitable for this medicine or should change use. For heart rate, blood pressure, breathing symptoms, stopping, swallowing or an added medicine, obtain review from a professional who can see the complete history, tests and medicine list.
- Mechanism information does not replace pharmacovigilance, interaction review or emergency assessment. For an acute serious problem, prioritise local emergency care; for other questions, contact a pharmacist or prescribing team with the actual pack and complete medicine list.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
SOURCE-TRACEABLE ARCHIVE
INDERAL LApropranolol hydrochloride
This page includes an exact current U.S. public-label package panel for INDERAL LA, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
U.S. DailyMed public label updated
DailyMed lists 1 Aug 2024 as the Updated date for the U.S. public label for INDERAL LA (propranolol hydrochloride) extended-release oral capsules. This page uses that record only to check 60 mg, 80 mg, 120 mg and 160 mg extended-release capsules and the 100-capsule bottle panels for NDC 62559-520-01, 62559-521-01, 62559-522-01 and 62559-523-01; this only supports label and product-identity checking, not actual marketing, stock, purchase, individual capsule count, capsule opening, co-use, switching or another-market status.
DailyMed (NLM): U.S. INDERAL LA propranolol hydrochloride extended-release oral-capsule public label (ANI; updated 1 Aug 2024) ↗
MARKET SCOPE
Market-record boundary
United States
Public label and four exact 100-capsule bottle panels linkedThe page separately displays the specified NDC and 100-capsule bottle for INDERAL LA propranolol hydrochloride extended-release capsules 60 mg, 80 mg, 120 mg and 160 mg. Release design and mg are only product-identity clues; they do not establish individual capsule count, capsule opening, actual marketing, stock, purchase, authenticity or interchangeability.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. label, SPL, NDC, English brand, package image or label holder; every market requires separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
With the same generic name propranolol, can INDERAL LA extended-release capsules be self-switched to conventional tablets by the same mg, or alternated with another beta blocker?
No. The label expressly says INDERAL LA should not be considered a simple mg-for-mg substitute for conventional propranolol. Release design, exact capsule, strength, package, label version, market and prescription are all part of product identity; have a pharmacist or prescriber check the actual packs and complete medicine list.
Do 60, 80, 120 or 160 mg on the capsule mean I can open it, reduce capsules or adjust it myself?
No. They are only labelled amounts per exact extended-release capsule in this U.S. label. This page provides no capsule-opening, individual capsule-count, timing, missed-use, doubling, stopping or substitution instruction; follow the actual prescription, current label for the exact product, and pharmacist or prescriber review.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.